Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07600749 | Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) | PHASE1 | NOT YET_RECRUITING | 120 | — | — | Jun 15, 2026 | Oct 4, 2029 | May 22, 2026 | - | — |
DLT is defined as the occurrence of protocol-specified toxicities, unless clearly related to disease progression or intercurrent illness.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with experience an AE will be reported.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-4884 Dose Escalation Schedule A | EXPERIMENTAL | Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met. |
| MK-4884 Dose Escalation Schedule B | EXPERIMENTAL | Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met. |
| Name | Type | Description |
|---|---|---|
| MK-4884 | DRUG | Oral Administration |
Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced (metastatic) solid tumors: * Colorectal carcinoma (CRC) * Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoi...